Donnatal

Product NDC: 17856-0423
11-digit product format: 178560423
Labeler code: 17856
Product ID: 17856-0423_42d4c5a0-3af9-481f-b29e-813b66090ba1
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: PHENOBARBITAL
Dosage form: ELIXIR
Route: ORAL
Labeler: Atlantic Biologicals Corps
Marketing category: UNAPPROVED DRUG OTHER
Marketing start: 2009-11-01
Marketing end: 0000-00-00
Substance: PHENOBARBITAL; HYOSCYAMINE SULFATE; SCOPOLAMINE HYDROBROMIDE; ATROPINE SULFATE
Active strength: 16 mg/5mL; mg/5mL; mg/5mL; mg/5mL
Pharmacologic classes: Anticholinergic [EPC],Cholinergic Antagonists [MoA],Anticholinergic [EPC],Cholinergic Antagonists [MoA],Cholinergic Muscarinic Antagonist [EPC],Cholinergic Muscarinic Antagonists [MoA]
DEA schedule: CIV
NDC exclude flag: No
Listing certified through: 2019-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 15 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	17856-0423		D	Discontinued by firm	2026-10-12
excluded product	product	17856-0423		I	Inactivated by FDA	2026-10-12
excluded package	package	17856-0423	17856-0423-2	D	Discontinued by firm	2026-10-12
excluded package	package	17856-0423	17856-0423-3	D	Discontinued by firm	2026-10-12
excluded package	package	17856-0423	17856-0423-4	D	Discontinued by firm	2026-10-12
excluded package	package	17856-0423	17856-0423-5	D	Discontinued by firm	2026-10-12
excluded package	package	17856-0423	17856-0423-8	D	Discontinued by firm	2026-10-12
excluded package	package	17856-0423	17856-0423-9	D	Discontinued by firm	2026-10-12
excluded package	package	17856-0423	17856-0423-2	I	Inactivated by FDA	2026-10-12
excluded package	package	17856-0423	17856-0423-3	I	Inactivated by FDA	2026-10-12
excluded package	package	17856-0423	17856-0423-4	I	Inactivated by FDA	2026-10-12
excluded package	package	17856-0423	17856-0423-5	I	Inactivated by FDA	2026-10-12
excluded package	package	17856-0423	17856-0423-6	I	Inactivated by FDA	2026-10-12
excluded package	package	17856-0423	17856-0423-8	I	Inactivated by FDA	2026-10-12
excluded package	package	17856-0423	17856-0423-9	I	Inactivated by FDA	2026-10-12

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 5 · 252 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-3	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-4	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-9	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-2	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-8	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-8	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-9	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-5	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-5	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-2	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-3	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-4	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	17856-0423-6	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-3	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-4	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-9	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-2	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-8	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-8	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-9	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-5	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-5	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-2	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-3	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-4	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	17856-0423-6	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-3	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-4	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-9	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-2	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-8	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-8	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-9	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-5	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-5	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-2	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-3	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-4	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	17856-0423-6	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-3	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-4	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-9	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-2	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-8	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-8	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-9	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-5	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-5	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-2	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-3	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-4	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	17856-0423-6	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
6c78bd43-efb4-4aeb-b7d8-eff1532f7822	Product name	4	20250801
41231c1e-8789-4da7-ac52-77fa90a85bf5	Product name	2	20250304
fe8ea78e-e1a4-44bf-a6b2-42eed76976bb	Product name	5	20250218
e77ab9a2-80cf-4832-bff0-469bbc7cbcd0	Product name	2	20250214
5f84b7a7-523a-f042-dffb-1dadcd9b2407	Product name	4	20240110
e3e67a66-d325-4d80-8f9d-059e736d7b00	Product name	1	20230912
0cbc6fb2-78c0-4b88-98f0-a4cc76ff95ca	Product name	1	20230719
04cd5dc0-102f-46cb-8dbc-ca38dd2628d0	Product name	3	20230317
dfd25202-b8d2-4628-9213-f3e0f9eafce5	Product name	4	20210513
4199bf9b-4718-828a-6dd6-ac2fbbd61687	Product name	1	20140508
4edd8af5-cea7-ae42-8023-e91c5335db1d	Product name	1	20140508
d3908afb-7784-440f-c406-88294732d36a	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Related label table
NDC	Related label
17856-0423-2	DONNATAL ELIXIR grape flavor 1 pint
17856-0423-3	DONNATAL ELIXIR grape flavor 1 pint
17856-0423-4	DONNATAL ELIXIR grape flavor 1 pint
17856-0423-5	DONNATAL ELIXIR grape flavor 1 pint
17856-0423-6	DONNATAL ELIXIR grape flavor 1 pint
17856-0423-8	DONNATAL ELIXIR grape flavor 1 pint
17856-0423-9	DONNATAL ELIXIR grape flavor 1 pint

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
17856-0423-2	Donnatal	15 mL in 1 CUP	ELIXIR	15	16
17856-0423-3	Donnatal	10 mL in 1 CUP	ELIXIR	10	16
17856-0423-4	Donnatal	5 mL in 1 CUP	ELIXIR	5	16
17856-0423-5	Donnatal	5 mL in 1 CUP	ELIXIR	5	16
17856-0423-6	Donnatal	5 mL in 1 CUP	ELIXIR	5	16
17856-0423-6	Donnatal	10 in 1 CASE	ELIXIR	10	16
17856-0423-8	Donnatal	15 mL in 1 CUP	ELIXIR	15	16
17856-0423-9	Donnatal	10 mL in 1 CUP	ELIXIR	10	16

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
17856-0423-3	ML - Milliliter	17856-0423	d6bdfe1b-0918-4a47-bb1c-85bffd7caf96	1	2013-05-02
17856-0423-5	ML - Milliliter	17856-0423	966e1aa6-040f-42f7-b4fb-dc59baa778e2	1	2013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
Atropine sulfate	ACTIVE INGREDIENT	03J5ZE7KA5	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
Hyoscyamine sulfate	ACTIVE INGREDIENT	F2R8V82B84	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
Phenobarbital	ACTIVE INGREDIENT	YQE403BP4D	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
Scopolamine hydrobromide	ACTIVE INGREDIENT	451IFR0GXB	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
Atropine	ACTIVE MOIETY	7C0697DR9I	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
Hyoscyamine	ACTIVE MOIETY	PX44XO846X	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
Phenobarbital	ACTIVE MOIETY	YQE403BP4D	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
Scopolamine	ACTIVE MOIETY	DL48G20X8X	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
FD&C BLUE NO. 1	INACTIVE INGREDIENT	H3R47K3TBD	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
FD&C RED NO. 3	INACTIVE INGREDIENT	PN2ZH5LOQY	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
GRAPE	INACTIVE INGREDIENT	6X543N684K	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
SACCHARIN SODIUM	INACTIVE INGREDIENT	SB8ZUX40TY	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
SORBITOL	INACTIVE INGREDIENT	506T60A25R	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
SUCROSE	INACTIVE INGREDIENT	C151H8M554	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12
WATER	INACTIVE INGREDIENT	059QF0KO0R	DONNATAL (PHENOBARBITAL ELIXIR) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	12

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
17856-0423	DONNATAL (PHENOBARBITAL) ELIXIR [ATLANTIC BIOLOGICALS CORPS]	16	Legacy NDC, 8 package rows	20180510_5d69ffc1-4608-4d73-ae91-838983bcf98d.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
YQE403BP4D	PHENOBARBITAL	50-06-6	PHENOBARBITAL
F2R8V82B84	HYOSCYAMINE SULFATE	6835-16-1	HYOSCYAMINE SULFATE
451IFR0GXB	SCOPOLAMINE HYDROBROMIDE	6533-68-2	SCOPOLAMINE HYDROBROMIDE
03J5ZE7KA5	ATROPINE SULFATE	5908-99-6	ATROPINE SULFATE

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
1046924	Donnatal 16.2 MG / 0.1037 MG / 0.0194 MG / 0.0065 MG in 5 mL Oral Solution	PSN	5d69ffc1-4608-4d73-ae91-838983bcf98d	16
1046787	PHENobarbital 16.2 MG / hyoscyamine sulfate 0.1037 MG / atropine sulfate 0.0194 MG / scopolamine HBr 0.0065 MG in 5 mL Oral Solution	PSN	5d69ffc1-4608-4d73-ae91-838983bcf98d	16
1046924	atropine sulfate 0.00388 MG/ML / hyoscyamine sulfate 0.0207 MG/ML / phenobarbital 3.24 MG/ML / scopolamine hydrobromide 0.0013 MG/ML Oral Solution [Donnatal]	SBD	5d69ffc1-4608-4d73-ae91-838983bcf98d	16
1046787	atropine sulfate 0.00388 MG/ML / hyoscyamine sulfate 0.0207 MG/ML / phenobarbital 3.24 MG/ML / scopolamine hydrobromide 0.0013 MG/ML Oral Solution	SCD	5d69ffc1-4608-4d73-ae91-838983bcf98d	16
1046787	atropine sulfate 0.0194 MG / hyoscyamine sulfate 0.1037 MG / phenobarbital 16.2 MG / scopolamine hydrobromide 0.0065 MG per 5 ML Oral Solution	SY	5d69ffc1-4608-4d73-ae91-838983bcf98d	16
1046924	Donnatal (atropine sulfate 0.00388 MG / hyoscyamine sulfate 0.0207 MG / phenobarbital 3.24 MG / scopolamine hydrobromide 0.0013 MG) per ML Oral Solution	SY	5d69ffc1-4608-4d73-ae91-838983bcf98d	16
1046924	Donnatal (atropine sulfate 0.0194 MG / hyoscyamine sulfate 0.1037 MG / phenobarbital 16.2 MG / scopolamine hydrobromide 0.0065 MG) per 5 ML Oral Solution	SY	5d69ffc1-4608-4d73-ae91-838983bcf98d	16
1046924	Donnatal (atropine sulfate 0.0388 MG / hyoscyamine sulfate 0.2074 MG / phenobarbital 32.4 MG / scopolamine hydrobromide 0.013 MG) per 10 ML Oral Solution	SY	5d69ffc1-4608-4d73-ae91-838983bcf98d	16

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Status
17856-0423-2	17856042302	15 mL in 1 CUP	15 ml	Historical
17856-0423-3	17856042303	10 mL in 1 CUP	10 ml	Historical
17856-0423-4	17856042304	5 mL in 1 CUP	5 ml	Historical
17856-0423-5	17856042305	5 mL in 1 CUP	5 ml	Historical
17856-0423-6	17856042306	5 mL in 1 CUP	5 ml	Historical
17856-0423-8	17856042308	15 mL in 1 CUP	15 ml	Historical
17856-0423-9	17856042309	10 mL in 1 CUP	10 ml	Historical

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
DONNATAL ELIXIR grape flavor 1 pint	Atlantic Biologicals Corps	2018-05-10	HUMAN PRESCRIPTION DRUG LABEL	16